Search

Displaying results 1641 - 1650 of 10000 in total
  1. Drug

    Alitretinoin

    go.drugbank.com/drugs/DB00523
    Approved

    An excess of tretinoin can be teratogenic. It is used in the treatment of psoriasis; acne vulgaris; and several other skin diseases. … An important regulator of gene expression during growth and development, and in neoplasms.

    Categories: Skin and Mucous Membrane AgentsProducts: Alitretan 10 mg Kapseln, Alitretan 30 mg Kapseln
  2. Drug

    Riociguat

    go.drugbank.com/drugs/DB08931
    ApprovedInvestigational

    Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for … the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH (pulmonary hypertension) after pulmonary endarterectomy in WHO FC II or III.

    Synonyms: Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminateProducts: Adempas 2 mg film-coated tablet, PULLMOGUAT® 2 MG TABLETA RECUBIERTA
  3. Target

    Interphotoreceptor matrix proteoglycan 2

    go.drugbank.com/bio_entities/BE0004942
    TargetHumans

    Chondroitin sulfate- and hyaluronan-binding proteoglycan involved in the organization of interphotoreceptor matrix; may participate in the maturation and maintenance of the light-sensitive photoreceptor outer segment. Binds heparin

    Synonyms: IPM 200, Interphotoreceptor matrix proteoglycan of 200 kDa
  4. Drug

    L-Glutamine

    go.drugbank.com/drugs/DB00130
    ApprovedInvestigationalNutraceutical

    An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical. … It is the principal carrier of nitrogen in the body and is an important energy source for many cells.

    Products: GLUTAVEN 250, NUTRIMED GLUTAMIN 100 GR (20X5)
  5. Drug

    Ambrisentan

    go.drugbank.com/drugs/DB06403
    ApprovedInvestigational

    In addition, it is approved in the United States for use in combination with tadalafil to reduce the risks of disease progression, hospitalization and to improve exercise ability. … As an endothelin receptor antagonist, Ambrisentan prevents endogenous endothelin peptide from constricting the muscles in blood vessels, allowing them to relax and permit a reduction in blood pressure.

    Products: INFINIX® 5 MG, VOLIBRIS 5 MG
  6. Drug

    Icosapent ethyl

    go.drugbank.com/drugs/DB08887
    ApprovedInvestigationalNutraceutical

    It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides. … FDA approved on July 26, 2012.

    Synonyms: E-EPA
  7. Drug

    Prazepam

    go.drugbank.com/drugs/DB01588
    ApprovedIllicit

    Prazepam is a benzodiazepine that is used in the treatment of anxiety disorders. It is a schedule IV drug in the U.S.

    Products: PRAZEPAM EG
  8. Drug

    Interferon alfa-n1

    go.drugbank.com/drugs/DB00011
    ApprovedWithdrawn

    Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated.

    Products: Wellferon Inj 10 000 000unit/ml, WELLFERON INYECTABLE 5 MU/ML
  9. Drug

    Glycine

    go.drugbank.com/drugs/DB00145
    ApprovedInvestigationalNutraceuticalVet approved

    It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.

    Mixtures: Aminosyn II 8.5% M In 20% Dextrose (dual Chamber), POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 2000 MLProducts: GLICINA IRRIGACION 1.5% M/V, % 1.5 GLISIN IRIGASYON ÇÖZELTİSİ, 3000 ML SETSİZ
  10. Drug

    Olaparib

    go.drugbank.com/drugs/DB09074
    ApprovedInvestigational

    [L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820] … [L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell

    Products: LYNPARZA® 100 MG, LYNPARZA (100 MG TABLET)